Another senior leader has left the Food and Drug Administration’s medical device center.
Douglas Kelly, deputy center director for science at the Center for Devices and Radiological Health, announced his immediate departure in a Sunday LinkedIn post.
After a career in venture capital, Kelly joined the CDRH in 2020, reporting to former director Jeff Shuren, and then Michelle Tarver, who became leader of the device center in October. During Kelly’s tenure, he helped negotiate the latest user fee agreement, allowing the FDA to receive up to $1.9 billion in fees from the medical device industry from 2023 to 2027.
Kelly also established the Total Product Lifecycle Advisory Program, which allows breakthrough device developers to meet earlier with FDA review teams and outside stakeholders, according to Kelly’s LinkedIn profile.
Kelly helped recruit industry leaders to the FDA, including Ross Segan, who joined the agency from Olympus in September as director of the Office of Product Evaluation and Quality, and Troy Tazbaz, who left Oracle to lead CDRH’s Digital Health Center of Excellence, according to the LinkedIn post.
Tazbaz left the agency in late January, and Segan was fired in a wave of cuts targeting probationary employees, who have been at the FDA for less than two years. The CDRH has since reinstated some of the fired employees. The FDA and the Department of Health and Human Services did not respond to questions about Kelly’s departure or whether Segan was offered the job back or had returned.
